COMPOUND USEFUL FOR THE TREATMENT OR PREVENTION OF COGNITIVE DISORDERS ASSOCIATED WITH DIABETES AND THE USE THEREOF

摘要

Described is the efficient synthesis of an easy to manipulate and utilize, soluble tartrate salt of a potent, reversible butyrylcholinesterase inhibitor, (-)-(3aS)-3a-methyl -1,2,3,3a,8,8a-hexahydropyrrolo-[2,3-b]indol-5-yl N-4'-isopropylphenylcarbamate ("MHI tartrate"), for use in altering the enzymatic activity of butyrylcholinesterase and/or acetylcholinesterase in a subject exhibiting or predicted to exhibit cognitive disorders associated with diabetes. Subjects may be suffering from or predicted to suffer from abnormal acetylcholinesterase and/or butyrylcholinesterase activity levels or from an inability to metabolize or catabolize blood sugar normally. The method comprises administering to the subject an effective amount of MHI tartrate dispensable in discrete pharmaceutically useful dosages. MHI tartrate effectively inhibits both acetylcholinesterase and butyrylcholinesterases and additionally is highly selective for butyrylcholinesterase over acetylcholinesterase.